Pathlight™ Multi-cancer MRD test
Use
Pathlight™ is a blood-based, multi-cancer minimal residual disease (MRD) test designed to enable clinicians to monitor cancer progression from early detection through relapse and metastasis. It delivers a 96% detection rate at baseline across all stages and subtypes of breast cancer and reports 100% sensitivity and specificity in clinical studies. The test focuses on large-scale genomic alterations called structural variants (SVs), which are less susceptible to technical noise, offering 20x greater analytical sensitivity than first-generation MRD tests.
Special Instructions
Pathlight is covered by Medicare for select indications. Results for personalized tumor fingerprint development and initial blood test are available 2 to 3 weeks from receipt of both tissue and blood at the laboratory. Subsequent blood test results are available within 1 to 3 days from receipt of blood at the laboratory. Physicians can contact client services to set up an account and start ordering tests.
Limitations
The test's reliance on structural variants over single nucleotide variants may impact certain patient populations differently, and its use is primarily indicated in breast cancer, with performance in other cancers being dependent on large-scale genomic alterations. While it achieves higher sensitivity and specificity, the test may not capture all genomic variations relevant in cancers with fewer SVs.
Methodology
NGS (WES)
Biomarkers
Result Turnaround Time
2-3 weeks
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided